The Claim
Among adults with atherosclerotic cardiovascular disease and ApoE4/E4 homozygosity, treatment with obicetrapib prevents 46% of participants from exceeding the pathological threshold of 0.42 pg/mL for plasma p-tau217 over a 12-month period compared to placebo.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults with heart disease and two copies of the ApoE4 gene, obicetrapib reduces the number of people whose plasma p-tau217 levels rise above 0.42 pg/mL over 12 months by 46% compared to those taking a placebo.
See the scientific wording
Among adults with atherosclerotic cardiovascular disease and ApoE4/E4 homozygosity, obicetrapib treatment prevents 46% of participants from exceeding the pathological threshold of 0.42 pg/mL for plasma p-tau217 over 12 months, compared to placebo, suggesting potential to delay transition to elevated Alzheimer’s biomarker status.
A pill blocks a protein that moves cholesterol between blood particles, causing good cholesterol particles to become smaller and more numerous. These small particles enter the brain and remove excess cholesterol from support cells, reducing toxic byproducts and oxidative damage. This stops the brain's nerve cells from accumulating abnormal tau proteins, preventing a key Alzheimer’s biomarker from rising.
What the research says
1 studyIn people with two copies of the ApoE4 gene and heart disease, a pill called obicetrapib helped keep a brain biomarker linked to Alzheimer’s from rising — while it kept getting worse in people who took a placebo. This suggests the pill might help delay early brain changes.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.